Jubilant Pharmova has been granted a patent for a stable radiopharmaceutical composition of tetrofosmin, providing high radiochemical purity and stability. The composition includes specific components and ratios, ensuring quality and effectiveness in diagnostic imaging procedures. GlobalData’s report on Jubilant Pharmova gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Jubilant Pharmova, Graphene oxide composites was a key innovation area identified from patents. Jubilant Pharmova's grant share as of January 2024 was 33%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11857647B2) discloses a reconstituted radiopharmaceutical composition that includes a first component comprising an aqueous solution of 99mTc pertechnetate and a second component with specific ingredients in precise amounts. The composition is free of certain additives and has a radiochemical purity of at least 90% after 12 hours of storage at a temperature of 2-30°C. The molar ratio of tetrofosmin disulfosalicylate to gentisic acid, key components of the second component, falls within a specified range, ensuring the desired characteristics of the radiopharmaceutical composition.
Furthermore, the patent details a method for preparing the reconstituted radiopharmaceutical composition, involving specific steps such as lyophilization and mixing with the aqueous solution of 99mTc pertechnetate. The composition's components are carefully selected and combined to maintain radiochemical purity and stability over time. The patent also highlights the importance of the ratio of tetrofosmin disulfosalicylate to stannous chloride dihydrate in achieving the desired properties of the radiopharmaceutical composition. Overall, the patent provides a comprehensive guide for creating a liquid radiopharmaceutical composition with specific ingredients and ratios to ensure efficacy and stability for medical applications.
To know more about GlobalData’s detailed insights on Jubilant Pharmova, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
